Carlberg M, Beart P M, Jarrott B
University of Melbourne, Clinical Pharmacology and Therapeutics Unit, Austin Hospital, Heidelberg, Victoria, Australia.
Eur J Pharmacol. 1990 Nov 20;191(1):107-10. doi: 10.1016/0014-2999(90)94103-5.
The 125I-labeled sulfated cholecystokinin (CCK) analogue, [D-Tyr25,Nle28,31]CCK-(25-33), bound saturably to membranes from rat cerebral cortex and to brain tissue sections. Competition studies suggested binding to sites of the CCKB subtypes. The high affinity for brain membranes (Kd = 0.14 nM) and high specific binding to brain sections (80-90% specific binding), as well as its high specific radioactivity, makes it a suitable ligand for autoradiographic studies of cholecystokinin receptors.
